Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib During and After HCT for Myelofibrosis
NCT07104799Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mivavotinib in myelofibrosis (MF), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose of Momelotinib at 28 days. Started Feb 2026; status: recruiting.
02
Drugs
mivavotinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07104799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104799.